The role of albumin-bound paclitaxel in metastatic breast cancer

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 6, 2011, Pages 469-471

  Russell, Christy ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BEVACIZUMAB; CREMOPHOR; DOCETAXEL; GEMCITABINE; IXABEPILONE; PACLITAXEL; PLATINUM; POLYSORBATE 80; TRASTUZUMAB;

ARTICLE; BREAST CANCER; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METASTASIS; NEUROPATHY; TUMOR GROWTH;

ALBUMINS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PACLITAXEL;

EID: 79959922628     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
2. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27:3611-3619.
3. Lobo C, Lopes G, Baez O, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-nega-tive metastatic breast cancer. Breast Cancer Res Treat. 2010;123:427-435.